藥理選擇英文版.doc_第1頁
藥理選擇英文版.doc_第2頁
藥理選擇英文版.doc_第3頁
藥理選擇英文版.doc_第4頁
藥理選擇英文版.doc_第5頁
已閱讀5頁,還剩31頁未讀, 繼續(xù)免費閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)

文檔簡介

Choose one correct answer (單選題)1. Pharmacology is ( )A. PharmacodynamicsB. PharmacokineticsC. Mechanism of drug actionD. Studies of interactions between drug and bodyE. Subject related to the medicinal chemistry and physiology2. 藥理學(xué)是研究( ) A藥物效應(yīng)動力學(xué) B藥物代謝動力學(xué) C藥物作用機理D藥物與機體相互作用的規(guī)律 E與藥物學(xué)和生理學(xué)相關(guān)的學(xué)科3. The contents of pharmcodynamics are ( )A. Clinical effect of drugB. Mechanism of drug actionC. The process that action of drug on the bodyD. Factors affecting the drug effectE. Factors affecting the drug process in the body4. 藥效學(xué)研究的內(nèi)容是( ) A藥物的臨床療效 B藥物的作用機理 C藥物對機體的作用規(guī)律D藥物療效的影響因素 E藥物體內(nèi)過程的影響因素5. The contents of pharmacokinetics are ( )A. Relationship between concentration and clinical effect of drugB. Relationship between blood concentration of drug and timeC. Factors affecting the drug absorptionD. Factors affecting the drug biotransformationE. The process that action of body on drug6. 藥動學(xué)研究的內(nèi)容是( ) A血藥濃度與臨床療效的關(guān)系 B血藥濃度與時間的變化規(guī)律 C藥物吸收的影響因素 D藥物生物轉(zhuǎn)化的影響因素 E機體對藥物的處置的動態(tài)變化7. The processes of drug in the body include ( )A. AbsorptionB. DistributionC. MetabolismD. ExcretionE. All of A, B, C and D8. 藥物在體內(nèi)的過程包括( )A. 吸收B. 分布C. 代謝D. 排泄E. 以上均對9. The mode by which most drugs get across the cell membrane are ( )A. Passive transportB. Simple diffusion C. Facilitated diffusionD. Filtration E. Pinocytosis 10. 大多數(shù)藥物的跨膜轉(zhuǎn)運方式是( ) A主動轉(zhuǎn)運 B 簡單擴散 C 易化擴散 D 濾過 E 胞飲11. The results of drug biotransformation are ( )A. Increased polarity to be easily eliminatedB. Increased activityC. Decreased or no toxicityD. Decreased or no activityE. All of A, B, C and D12. 藥物經(jīng)生物轉(zhuǎn)化后( ) A 極性增加,利于消除 B 活性增大 C毒性減弱或消失 D 活性減弱或消失 E 以上都有可能13. The main excretion pathways of drug or the metabolite are ( )A. KidneyB. BileC. MilkD. Sweat E. Respiratory tract14. 藥物或其代謝物排泄的主要途徑是( )A 腎 B 膽汁 C 乳汁 D 汗腺 E 呼吸道15. The characteristics of active transport are ( )A. Along with the concentration gradient; energy not needed; carrier neededB. Along with the concentration gradient; energy needed; carrier neededC. Against with the concentration gradient; energy needed; no competitionD. Against with the concentration gradient; energy needed; can be saturatedE. Against with the concentration gradient; energy not needed; can be saturated16. 主動轉(zhuǎn)運的特點是( ) A 順濃度差,不耗能,需載體 B 順濃度差,耗能,需載體 C 逆濃度差,耗能,無競爭現(xiàn)象 D 逆濃度差,耗能,有飽和現(xiàn)象 E 逆濃度差,不耗能,有飽和現(xiàn)象17. The characteristics of first order kinetics are ( )A. Eliminated by constant ratio; t1/2 is not a constantB. Eliminated by constant amount; t1/2 is a constantC. Eliminated by constant amount; t1/2 is not a constantD. Eliminated by constant ratio; t1/2 is a constantE. t1/2 changes with the change of blood concentration of drug18. 一級消除動力學(xué)的特點是( ) A 恒比消除,tl/2不定 B 恒量消除, tl/2恒定 C 恒量消除,tl/2不定 D恒比消除, tl/2恒定 E tl/2隨血藥濃度變化而變化 19. The t1/2 of one drug is 10 h, how long will the drug be nearly completely eliminated if given once? ( )A. About 10 hB. About 2 dC. About 1 dD. About 20 hE. About 5 d20. 某藥半衰期為10小時,一次給藥后,藥物在體內(nèi)基本消除時間為( ) A 10小時左右 B 2天左右 C 1天左右 D 20小時左右 E 5天左右21. The blood concentration of phenytoin increased if combined with chloromycin because chloromycin can ( )A. Increase the absorption of phenytoinB. Compete the plasma protein with phenytoinC. Increase the bioavailability of phenytoinD. Inhibit the activity of liver drug metabolism enzymeE. Reduce the excretion of phenytoin from urine 22. 氯霉素與苯妥英鈉合用時,可使苯妥英鈉血藥濃度升高,是因為氯霉素能( ) A 增加吸收 B競爭血漿蛋白結(jié)合部位 C提高生物利用度 D抑制肝藥酶 E減少尿中排泄23. How to accelerate the excretion of Phenobarbital from urine if it is overdosed ? ( )A. Alkalify the urine to increase the dissociation of Phenobarbital, resulting in the increased reabsorption by renal tubularB. Alkalify the urine to decrease the dissociation of Phenobarbital, resulting in the increased reabsorption by renal tubularC. Alkalify the urine to increase the dissociation of Phenobarbital, resulting in the decreased reabsorption by renal tubularD. acidify the urine to increase the dissociation of Phenobarbital, resulting in the decreased reabsorption by renal tubularE. None of A, B, C and D24. 苯巴比妥過量中毒, 為了促使其加速排泄, 應(yīng)( ) A 堿化尿液, 使解離度增大, 增加腎小管 再吸收 B 堿化尿液, 使解離度增小, 增加腎小管再吸收 C 堿化尿液, 使解離度增大, 減少腎小管再吸收 D 酸化尿液, 使解離度增大, 減少腎小管再吸收 E 以上均不對25. The bioavailability of drug is ( )A. The blood amount of drug absorbed from the gastrointestinal tractB. The blood concentration of drug absorbed from the gastrointestinal tractC. The amount of drug in the action citeD. The percentage of drug in the blood to the dose given at any routes E. None of A, B, C and D26. 藥物的生物利用度是指( )A.藥物經(jīng)胃腸道進入血液循環(huán)的量B.藥物經(jīng)胃腸道進入血液循環(huán)的濃度C.藥物吸收到達作用點的量D.任何給藥途徑下藥物進入血液循環(huán)的百分比 E.以上均不對27. The plasma half life (t1/2) is ( )A. The time during which 50% of drug is excreted from the bodyB. The time during which 50% of drug is biotransformedC. Half of the time during which the drug completely disappeared from bloodD. The time during which drug concentration decreases by halfE. The time during which drug effect decreases by half28. 藥物的血漿半衰期是( ) A 50%藥物從體內(nèi)排出所需要的時間 B 50%藥物進行了生物轉(zhuǎn)化 C 藥物從血漿中消失所需要的時間的一半 D 血漿濃度下降一半所需要的時間 E 藥物作用強度減弱一半所需要的時間29. The main routes through which the first pass effect of drug occurs ( )A. Intravenous injectionB. Subcutaneous injectionC. Intramuscle injectionD. Oral administrationE. Inhalation 30. 藥物首過消除主要發(fā)生于 ( ) A 靜脈注射 B 皮下注射 C 肌肉注射 D口服給藥 E 吸入給藥31. At which dose the side effect will occurs ( )A. ExtremeB. TherapeuticC. ToxicD. LD50E. Minimal toxic32. 下列哪種劑量會產(chǎn)生副作用( ) A 極量 B 治療量 C 中毒量 D LD50 E 最小中毒量33. The characteristics of receptor antagonist are ( )A. Has no affinity but has intrinsic activityB. Has no affinity as well as no intrinsic activityC. Has affinity but has no intrinsic activityD. Has affinity as well as intrinsic activityE. None of A, B, C and D34. 阻斷藥的特點是( ) A 對受體無親和力,但有內(nèi)在活性 B對受體無親和力,也無內(nèi)在活性 C 對受體有親和力,但無內(nèi)在活性 D對受體有親和力,也有內(nèi)在活性 E 以上均不對35. The characteristics of competitive antagonist are ( )A. Strong affinity and intrinsic activityB. Strong affinity and weak intrinsic activityC. Not relevant with affinity and intrinsic activityD. Strong affinity and no intrinsic activity, irreversible combination with receptorE. Strong affinity and no intrinsic activity, competition for the same receptor with agonist 36. 競爭性桔抗劑( )A親和力及內(nèi)在活性都強 B具有一定親和力但內(nèi)在活性弱 C與親和力和內(nèi)在活性無關(guān) D有親和力,無內(nèi)在活性,與受體不可逆性結(jié)合E有親和力,無內(nèi)在活性,與激動劑競爭相同受體37. The characteristics of noncompetitive antagonist are ( )A. Strong affinity and intrinsic activityB. Strong affinity and weak intrinsic activityC. Not relevant with affinity and intrinsic activityD. Strong affinity and no intrinsic activity, irreversible combination with receptorE. Strong affinity and no intrinsic activity, competition for the same receptor with agonist 38. 非競爭性桔抗劑( )A親和力及內(nèi)在活性都強 B具有一定親和力但內(nèi)在活性弱 C與親和力和內(nèi)在活性無關(guān) D有親和力,無內(nèi)在活性,與受體不可逆性結(jié)合 E有親和力,無內(nèi)在活性,與激動劑競爭相同受體39. The action mode of drug ( )A. LocalB. Systemic C. DirectD. IndirectE. All of A, B, C and D40. 藥物的作用方式是( ) A 局部作用B 全身作用C 直接作用D 間接作用E 以上全是41. Therapeutic effect and adverse effect of drug refer to ( )A. The selectivity of drug actionB. Dualism of drug actionC. Basic action of drugD. Mechanism of drug actionE. Mode of drug action42. 治療作用和不良反應(yīng)是( ) A 藥物作用的選擇性 B 藥物作用的兩重性 C 藥物的基本作用 D 藥物的作用機制 E 藥物作用的方式43. Which one has the greatest therapeutic index ( )A. drug A: LD50=500mg ED50=100mgB. drug B: LD50=500mg ED50=25mgC. drug C: LD50=500mg ED50=50mgD. drug D: LD50=50mg ED50=5mgE. drug E: LD50=50mg ED50=25mg44. 化療指數(shù)最大的藥物是( ) A 藥50=500mg ED50=100mg B 藥50=500mg ED50=25mg C 藥50=500mg ED50=50mg D 藥50=50mg ED50=5mg E E藥50=50mg ED50=25mg45. Which order is correct for the potency of the drugs shown in the following figure ( )A. ABCB. ACBC. BACD. BCAE. CBA EffectBCADose46. 圖中所示甲乙丙三藥,其效價強度比較為( )A 甲乙丙 B 甲丙乙 C 乙甲丙 D 乙丙甲 E 丙乙甲 乙丙甲效應(yīng)劑量 47. Toxicity of drug ( )A. Is not relevant with the doseB. Occurs at the therapeutic doseC. Is caused by overdoseD. Is secondary to the therapeutic effectE. Is allergic reaction48. 毒性反應(yīng)( ) A 與劑量無關(guān) B 在治療量下出現(xiàn) C 因用藥劑量過大或用藥時間過長引起 D 是治療作用引起的不良后果 E 是藥物引起的變態(tài)反應(yīng)49. The phenomenon that the effect can be reached by increasing the dose of drug after long duration is ( )A. Drug resistanceB. Drug toleranceC. Drug addictionD. TachyphylaxisE. Specificness50. 長期用藥,需要增加劑量才能發(fā)揮療效的現(xiàn)象,稱之為( ) A耐藥性B耐受性C成癮性D快速耐受性E特異性51. The phenomenon that the sensitivity of drug to bacteria decreases or even disappears after long duration is ( )A. Drug resistanceB. Drug toleranceC. Drug addictionD. TachyphylaxisE. Specificness52. 長期用藥,病原菌對藥物敏感性下降甚至失效的現(xiàn)象,稱之為( ) A耐藥性B耐受性C成癮性D快速耐受性E特異性53. Where does N1 receptor distribute? ( )A. Ganglion cellB. Myocardial cellC. Vascular smooth muscle cellD. Gastrointestinal smooth muscle cellE. Skeletal muscle cell54. N1受體主要位于 ( ) A 神經(jīng)節(jié)細(xì)胞 B 心肌細(xì)胞 C 血管平滑肌細(xì)胞 D 胃腸平滑肌 E 骨骼肌細(xì)胞55. What is the receptor by activating which the dilatation of bronchus smooth muscle occurs? ( )A. aB. b1C. H1D. b2E. M56. 興奮時產(chǎn)生舒張支氣管平滑肌效應(yīng)的主要受體是( ) A a受體 B b1受體 C H1受體 D b2受體 M受體57. Which is the main effect produced by activation of b1 receptor? ( )A. Dilatation of bronchus smooth muscleB. Increase of cardiac muscle contraction forceC. Contraction of skeletal muscleD. Contraction of gastrointestinal muscleE. Increase of secretion of gland58. 下述哪種是b1受體興奮的主要效應(yīng) ( ) A 舒張支氣管平滑肌 B 加強心肌收縮 C 骨骼肌收縮 D 胃腸平滑肌收縮 E 腺體分泌59. The rate-limiting enzyme which catalyzes the synthesis of noradrenaline is ( )A. CholinesteraseB. Choline acetylaseC. Monoamine oxidaseD. Dopa decarboxylaseE. Tyrosine hydroxylase60. 去甲腎上腺素合成的限速酶是 ( ) A膽堿酯酶 B膽堿乙?;?C單胺氧化酶 D多巴脫羧酶 E酪氨酸羥化酶61. The enzyme which can inactivate the noradrenaline is ( )A. Monoamine oxidaseB. Cholinesterase C. Thyroid peroxidaseD. Synthetase of mucopeptide E. Angiotensin-converting enzyme 62. 主要使去甲腎上腺素滅活的酶是 ( )A 單胺氧化酶 B 膽堿酯酶 C 甲狀腺過氧化物酶 D粘肽合成酶 E血管緊張素轉(zhuǎn)化酶63. Enzyme which can be reversibly inhibited by neostigmine is ( )A. Monoamine oxidaseB. Cholinesterase C. Thyroid peroxidaseD. Synthetase of mucopeptide E. Angiotensin-converting enzyme 64. 新斯的明可逆性抑制的酶是A 單胺氧化酶 B 膽堿酯酶 C 甲狀腺過氧化物酶D粘肽合成酶 E血管緊張素轉(zhuǎn)化酶65. Which effect is not produced by activating the M receptor? ( )A. Decrease of heart rateB. Contraction of gastrointestinal smooth muscle C. Contraction of gastrointestinal sphincter muscleD. Dilatation of sphincter muscle of urinary bladderE. Contraction of iris sphincter muscle (myosis)66. 下列哪種效應(yīng)不是通過激動M受體實現(xiàn)的 ( ) A心率減慢 B胃腸道平滑肌收縮 C胃腸道括約肌收縮 D膀胱括約肌舒張E虹膜括約肌收縮(縮瞳)67. Which description is not correct? ( )A. The adrenoceptor in bronchus smooth muscle is 2 receptorB. The cholinoceptor in nerve ganglion is N1 receptorC. Atropine is a anticholine drugD. The cholinoceptor in motor end plate is N2 receptorE. Pilocarpine is a postganglionic anitcholinergic drug68. 下列描述哪項有錯?( ) A 支氣管平滑肌上的腎上腺素受體是2受體 B 神經(jīng)節(jié)上的膽堿能受體是1受體 C 阿托品是抗膽堿藥 D 運動神經(jīng)終板上的膽堿能受體是2受體 E 毛果蕓香堿是節(jié)后抗膽堿藥69. Which one describing the clinical use of neosigmine is not correct? ( )A. Myasthenia gravisB. Paroxysmal supraventricular tachycardiaC. Angina caused by spasm of smooth muscleD. Generally not used for Myotica E. Rescue the toxicity by non-depolarizing muscular relaxant70. 有關(guān)新斯的明的臨床用途下列錯誤的是 ( ) A 重癥肌無力 B 陣發(fā)性室上性心動過速 C 平滑肌痙攣性絞痛 D通常不作眼科縮瞳藥 E 解救非去極化肌松藥中毒71. Which one is not the indication of anticholinesterase drug? ( )A. Myasthenia gravisB. Abdominal distensionC. Urinary retentionD. Atrial ventricular blockE. Paroxysmal supraventricular tachycardia72. 抗膽堿酯酶藥的適應(yīng)癥不包括 ( ) A 重癥肌無力B 腹脹氣C 尿潴留D 房室傳導(dǎo)阻滯E 陣發(fā)性室上性心動過速73. Drug which can obviously stimulate skeletal muscle is ( )A. AtropineB. TubocurarineC. PropranololD. NeostigmineE. Phentolamine 74. 興奮骨骼肌作用明顯的藥物是 A 阿托品 B 筒箭毒堿 C 普萘洛爾(心得安) D 新斯的明 E 酚妥拉明75. Drug which can produce the effect of mydriasis is ( )A. PilocarpineB. Neostigmine C. AtropineD. PrazosinE. Morphine 76. 滴眼產(chǎn)生擴瞳效應(yīng)的藥物是 A 毛果蕓香堿 B 新斯的明 C 阿托品D 哌唑嗪E 嗎啡 77. The reason that pyraloxime iodide can rescue the toxicity by organophosphorus compounds is ( )A. Renaturation of cholinesteraseB. Directly antagonize the acetylcholineC. Block the M receptorD. Block the N receptorE. None of A, B, C and D78. 碘解磷定解救有機磷酸酯類(農(nóng)藥)中毒是因為 A能使失去活性的膽堿酯酶復(fù)活 B能直接對抗乙酰膽堿的作用 C有阻斷M膽堿受體的作用 D有阻斷N膽堿受體的作用 E 以上都不是79. The reason that organophosphorus compounds can cause toxicity is ( )A. Reversible inhibition of cholinesteraseB. Irreversible inhibition of cholinesteraseC. Direct inhibition of M and N receptorD. Direct activation of M and N receptorE. Enhancement of release of acetylcholine by motor nerve ending80. 有機磷農(nóng)藥中毒的原理 A易逆性膽堿酯酶抑制劑B 難逆性膽堿酯酶抑制劑 C直接抑制M受體,N受體 D直接激動M受體,N受體 E促進運動神經(jīng)末梢釋放 Ach81. Which drug can cause high intraocular pressure? ( )A. PilocarpineB. Atropine C. AdrenalineD. Noradrenaline E. Chlorpromazine 82. 眼內(nèi)壓升高可由何藥引起 A 毛果蕓香堿 B 阿托品 C 腎上腺素 D 去甲腎上腺素 E 氯丙嗪83. Which effect is not produced by activating the receptor? ( )A. Dilatation of bronchusB. Vasorelaxation of skeletal muscleC. Fast heart rateD. Strong contraction force of cardiac muscleE. Contraction of detrusor of bladder84. 下列哪些效應(yīng)不是通過激動受體產(chǎn)生的 A 支氣管舒張 B 骨骼肌血管舒張 C 心率加快 D心肌收縮力增強 E膀胱逼尿肌收縮85. Which one is correct on the description of adrenaline?A. Directly activate ,1,2 receptorB. Strongly activate ,receptor, weakly activate receptorC. Activate ,, DA receptorD. Directly antagonize ,1,2 receptorE. Activate receptor86. 關(guān)于腎上腺素的描述正確的是 A 直接激動,1,2受體 B 主要激動受體,微弱激動受體 C 激動,DA受體 D 直接拮抗,1,2受體 E 主要激動受體87. Which description about dobutamine is correct? ( )A. Selectively activate bl receptorB. Selectively activate b2 receptorC. Activate both bl and b2 receptorsD. Weakly activate b receptorE. Activate a, bl and DA receptor88. 多巴酚丁胺A選擇性激動bl受體 B選擇性激動b2受體 C對bl和b2受體都有激動作用 D對b受體作用很弱 E對a、bl和多巴胺受體都有激動作用89. Which drug is immediately i.m given once allergic shock is induced by penicillin? ( )A. Adrenocortical hormoneB. Calcium chlorideC. Noradrenaline D. AdrenalineE. Atropine90. 青霉素過敏性休克一旦發(fā)生,應(yīng)立即注射 A 腎上腺皮質(zhì)激素B 氯化鈣C 去甲腎上腺素 D 腎上腺素 E 阿托品91. Which disease can not be treated by isoprenaline? ( )A. Bronchial asthmaB. Cardiac asthmaC. ShockD. Cardiac arrestE. Atrioventricular block92. 下列哪一情況不能用異丙腎上腺素治療?A 支氣管哮喘 B 心源性哮喘 C 休克 D 心跳驟停 E 房室傳導(dǎo)阻滯93. Which description on salbutamol is correct? ( )A. Selectively activate bl receptorB. Selectively activate b2 receptorC. Activate both bl and b2 receptorsD. Weakly activate b receptorE. Activate a, bl and DA receptor94. 沙丁胺醇A選擇性激動bl受體 B選擇性激動b2受體 C對bl和b2受體都有激動作用 D對b受體作用很弱 E對a、bl和多巴胺受體都有激動作用95. Which drug can reverse the BP raising effect by adrenaline? ( )A. PhentolamineB. NeostigmineC. PilocarpineD. EphedrinE. Atropine96. 能使腎上腺素升壓作用翻轉(zhuǎn)的藥物是A酚妥拉明B 新斯的明C 毛果蕓香堿D 麻黃堿E 阿托品97. Which contraindication is related to the propranolol? ( )A. GlaucomaB. Abdominal distentionC. Urinary retentionD. Prostatic hypertrophyE. Bronchial asthma98. 與普萘洛爾有關(guān)的禁忌癥是 A 青光眼 B 腹脹氣 C 尿潴留 D前列腺肥大 E支氣管哮喘99. The reason that phentolamine dilates the vessel is ( ).A. Blockade of 1 receptor in postsynaptic membraneB. Activation of M receptorC. Activation of receptor in presynaptic membraneD. Blockade of 2 receptor in presynaptic membraneE. Activation of DA receptor100. 酚妥拉明舒張血管的原理是 A 阻斷突觸后膜1受體B 主要奮M受體 C 興奮突觸前膜受體D 主要阻斷突觸前膜2受體 E 激動多巴胺受體 101. Which drug can induce the local necrosis if it leaks out the vessel? ( )A. AdrenalineB. Atropine C. IsoprenalineD. DopamineE. Noradrenaline102. 靜滴外漏易致局部壞死的藥物是 A 腎上腺素 B 阿托品 C 異丙腎上腺素 D 多巴胺 E 去甲腎上腺素103. What is the mechanism by which antipyretic analgesic reduces the fever? ( )A. Inhibition of synthesis of central PGB. Inhibition of synthesis of peripheral PGC. Inhibition of degradation of central PGD. Inhibition of degradation of peripheral PGE. Enhancement of release of central PG104. 解熱鎮(zhèn)痛藥的退熱作用機制是: A.抑制中樞PG合成 B.抑制外周PG合成 C.抑制中樞PG降解 D.抑制外周PG降解 E.增加中樞PG釋放105. What is the mechanism by which antipyretic analgesic relieves the pain? ( )A. Blockade of impulse transduction of afferent nerveB. Reduction of sensitivity of sensory fiber sensorC. Inhibitio

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論